| Nickname | Sema | Tirz | Reta |
|---|
| Brand names | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound | None (Investigational) |
|---|
| Developer | Novo Nordisk | Eli Lilly | Eli Lilly |
|---|
| Receptors targeted | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + glucagon |
|---|
| Headline weight-loss result | ~14.9% at 68 weeks | ~22.5% at 72 weeks at 15 mg | ~28.3% at 80 weeks at 12 mg |
|---|
| FDA status (U.S.) | Approved for diabetes and obesity | Approved for diabetes and obesity | Investigational, awaiting FDA filing |
|---|
| Most common side effects | GI: nausea, vomiting, diarrhea | GI: nausea, vomiting, diarrhea | GI effects plus skin tingling at higher doses |
|---|
